Our goal is to become a leading dermatology focused biopharmaceutical company. We intend to focus our initial efforts on completing the FB-401 clinical development to show its safety and efficacy in treating inflammatory skin diseases including AD. After obtaining FDA approval for FB-401, our focus will be on bringing FB-401 to market in order to address the significant unmet need for safe and effective AD therapy for pediatric as well as adult patients.